Literature DB >> 2373491

Secondary central nervous system involvement by non-Hodgkin's lymphoma: the risk factors.

R Liang1, E Chiu, S L Loke.   

Abstract

The risk of secondary central nervous system (CNS) was estimated in 833 cases of non-Hodgkin's lymphoma diagnosed between January 1975 and December 1988. Fifty-one of them had CNS disease (51/833, 6.1 per cent). No case of low grade lymphoma developed CNS disease. However, 6.5 per cent and 16.7 per cent of patients with intermediate and high grade lymphomas, respectively, had secondary CNS involvement. Stage IV disease and the presence of B symptoms were also associated with an increased risk of CNS disease. Significantly higher incidence of CNS disease was seen in patients with lymphoma involving orbit (43 per cent), testis (40 per cent), peripheral blood (33 per cent), bone (29 per cent), nasal/paranasal sinuses region (23 per cent) and bone marrow (20 per cent). CNS prophylaxis is recommended to patients with an increased risk of CNS disease.

Entities:  

Mesh:

Year:  1990        PMID: 2373491     DOI: 10.1002/hon.2900080305

Source DB:  PubMed          Journal:  Hematol Oncol        ISSN: 0278-0232            Impact factor:   5.271


  11 in total

Review 1.  Central nervous system disease in hematologic malignancies: historical perspective and practical applications.

Authors:  Ching-Hon Pui; Eckhard Thiel
Journal:  Semin Oncol       Date:  2009-08       Impact factor: 4.929

Review 2.  Leukemic and lymphomatous meningitis: incidence, prognosis and treatment.

Authors:  Marc C Chamberlain; Craig Nolan; Lauren E Abrey
Journal:  J Neurooncol       Date:  2005-10       Impact factor: 4.130

Review 3.  Secondary central nervous system lymphoma.

Authors:  Naoto Tomita; Fumio Kodama; Heiwa Kanamori; Shigeki Motomura; Yoshiaki Ishigatsubo
Journal:  Int J Hematol       Date:  2006-08       Impact factor: 2.490

Review 4.  Central nervous system prophylaxis in non-Hodgkin lymphoma: who, what, and when?

Authors:  Chan Yoon Cheah; John F Seymour
Journal:  Curr Oncol Rep       Date:  2015-06       Impact factor: 5.075

5.  Central nervous system involvement in AIDS-related lymphomas.

Authors:  Stefan K Barta; Jitesh Joshi; Nicolas Mounier; Xiaonan Xue; Dan Wang; Josep-Maria Ribera; Jose-Tomas Navarro; Christian Hoffmann; Kieron Dunleavy; Richard F Little; Wyndham H Wilson; Michele Spina; Lionel Galicier; Ariela Noy; Joseph A Sparano
Journal:  Br J Haematol       Date:  2016-04-07       Impact factor: 6.998

6.  Assessment of free light chains in the cerebrospinal fluid of patients with lymphomatous meningitis - a pilot study.

Authors:  B Hildebrandt; C Müller; A Pezzutto; Pt Daniel; B Dörken; C Scholz
Journal:  BMC Cancer       Date:  2007-10-03       Impact factor: 4.430

7.  Liposomal cytarabine in the prophylaxis and treatment of CNS lymphoma: toxicity analysis in a retrospective case series study conducted at Polish Lymphoma Research Group Centers.

Authors:  Wojciech Jurczak; Renata Kroll-Balcerzak; Sebastian Giebel; Maciej Machaczka; Agnieszka Giza; Tomasz Ogórka; Szymon Fornagiel; Justyna Rybka; Tomasz Wróbel; Beata Kumiega; Aleksander B Skotnicki; Mieczysław Komarnicki
Journal:  Med Oncol       Date:  2015-02-26       Impact factor: 3.064

8.  On chip analysis of CNS lymphoma in cerebrospinal fluid.

Authors:  Anna Turetsky; Kyungheon Lee; Jun Song; Randy J Giedt; Eunha Kim; Alexandra E Kovach; Ephraim P Hochberg; Cesar M Castro; Hakho Lee; Ralph Weissleder
Journal:  Theranostics       Date:  2015-04-17       Impact factor: 11.556

9.  Secondary infiltration of the central nervous system in patients with diffuse large B-cell lymphoma.

Authors:  Talita Maira Bueno da Silveira da Rocha; Fortier Sérgio Costa; Maeva Seo Gomes Pinto; Igor Campos da Silva; Roberto Pinto Paes; Carlos Sérgio Chiattone
Journal:  Rev Bras Hematol Hemoter       Date:  2013

10.  Isolated cerebellar hypermetabolism on FDG PET in a case of remitted primary breast lymphoma.

Authors:  Arun Kumar Reddy; Sampath Santhosh; Bhagwant Rai Mittal; Anish Bhattacharya; Suresh C Sharma
Journal:  Indian J Nucl Med       Date:  2014-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.